N/A N=98 Testing Training Programs to Improve Children's Pedestrian Behaviors
Child Behavior
Primary: Index of Crossing Safely: Hit by Car — 0.15; .26; 0.49 proportion of trials
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=110 Developing a Tool to Support Shared Decision Making Post-Concussion Between Adolescents, Parents and Clinicians
Concussion, Brain
Primary: Decisional Regret — 1.68; 2.00; 1.80; 1.77 Score on a scale — p=0.18
N/A N=28 Feasibility of a Culturally Adapted Emotional-Behavioral Prevention Program for American Indian Children
Anxiety Disorder · Depressive Disorder
Primary: Post-Intervention Youth-reported Anxiety Disorder Symptoms From Pre- to Post-Intervention — .94 mean score on scale
N/A N=313 Linking Inter-professional Newborn and Contraception Care
Family Planning · Contraception · PostPartum
Primary: Number of Patients Who Receive Contraception by Two Months Postpartum — 474; 339 Participants — p=0.12
N/A N=60 Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)
Colorectal Cancer
Primary: Feasibility as Measured by Study Accrual — 62 participants
Phase 2 N=33 A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
Amyloidosis
Primary: Within-Participant Coefficient of Variation [wCV] Associated With the Quantification (SUVmax) of Radioactivity Associated With Organ-Level Radiotracer Uptake — 14.58…
Phase 3 N=370 A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee
Osteoarthritis Pain of the Knee
Primary: Change From Baseline to Week 12 in WOMAC Pain Score (Intent-to-treat Set) — -4.6; -5.4 score on a scale
Phase 2 N=64 Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
Thromboembolism
Primary: Rate of Eligible Individuals Enrolled and Retained Through Full Study Procedures — 694; 611; 64; 61 participants
Phase 3 N=598 Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
Alzheimer Disease
Primary: Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control) — 1.71; 1.34 score on a scale
N/A N=153 Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Infectious Disease · Cancer · Coronavirus Infection
Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…
Phase 4 N=121 A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Frequency (Number) of Ocular and Non-ocular Treatment Emergent Adverse Events (TEAE). — 36.5; 60; 40; 21.2 Percentage of participants
N/A N=22 Transcranial Magnetic Stimulation for BECTS
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
Phase 1 N=40 Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
Ovarian Carcinoma · Soft Tissue Sarcoma
Primary: Dose Escalation Part: Establish the Recommended Phase II Dose (RP2D), the Maximum Tolerated Dose (MTD) Evaluated on the First Cycle (D1 to D21), the Safety Profile, and…
Phase 3 N=576 A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
Asthma
Primary: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 — 0.279; 0.174 liter — p=<0.001
Phase 3 N=60 Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study
HIV · Pregnancy
Primary: AUC0-24 of DTG in Pregnant Women in Third Trimester and 2 Weeks Postpartum — 35322; 40127 ng*h/mL